Navigation Links
Abiraterone: Indication of considerable added benefit in certain patients
Date:1/6/2012

Abiraterone (trade name: Zytiga) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy.

IQWiG finds an indication of a considerable added benefit of abiraterone in patients who are not eligible for further treatment with docetaxel. In contrast, an added benefit is not proven in patients who can still be treated with docetaxel, as the dossier submitted by the drug manufacturer provides inadequate information for this group of patients.

Separate assessment for two groups of patients

In accordance with the specifications of the Federal Joint Committee (G-BA), IQWiG separately assessed abiraterone in two groups of patients. The G-BA has specified different appropriate comparator therapies for the two groups.

The "best supportive care population" contains patients who are not eligible for further treatment with docetaxel. The appropriate comparator therapy for this group is palliative treatment with dexamethasone, prednisone, prednisolone or methylprednisolone, as well as "best supportive care".

"Best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms (e.g. adequate pain therapy) and improve quality of life.

The "docetaxel-retherapy population" comprises patients who are still eligible for further treatment with docetaxel. The appropriate comparator therapy for this patient population is docetaxel in combination with prednisone or prednisolone.

Indication of increase in survival and delay in consequences of disease

One study (COU-AA-301), which considers patient-relevant outcomes and provides relevant data, was included in the assessment of added benefit in the "best supportive care population". This study compared treatment with abiraterone versus placebo, in each case combined with prednisone and "best supportive care".

IQWiG finds an indication of an added benefit in patients treated with abiraterone: the above study provides indications that abiraterone can prolong survival and delay consequences of prostate cancer, such as fractures or operations due to bone metastases. In addition, the "time to pain progression" was prolonged in study participants receiving abiraterone.

IQWiG classifies the extent of this added benefit as "considerable". The corresponding legal ordinance has specified three grades to determine the extent of added benefit: "minor", "considerable" and "major".

The study data presented on health-related quality of life assessments cannot be used; an added benefit of abiraterone is therefore not proven for this outcome.

The indications of advantages for abiraterone are not accompanied by proof of greater harm.

Added benefit in the docetaxel-retherapy population not proven

The manufacturer presented inadequate data for the "docetaxel-retherapy population". The required search in trial registries was missing in the dossier. Moreover, studies presented by the manufacturer, such as indirect comparisons and one-arm studies, cannot be used due to deficits in methods and content. An added benefit in this patient group is therefore not proven.

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.


'/>"/>
Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Boceprevir: Indication of added benefit for specific patients
2. Prasugrel: Indications of an additional benefit for some patients, but also of greater harm
3. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
4. Indications of Alzheimers disease may be evident decades before first signs of cognitive impairment
5. Early indications of Parkinsons disease revealed in dream sleep
6. Ticagrelor: Considerable added benefit for specific patients
7. Considerable proportion of patients with advanced cancer continue to undergo common cancer screening
8. Pirfenidone: Extent of added benefit assessed
9. AML patients have high response rate with vorinostat added to treatment
10. Calorie count plus points based on added sugars, sodium, and saturated and trans fats recommended as new front-of-package nutrition labeling system
11. Hospitals encouraged to consider value-added service of hospital-based radiology groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... "ProDrop 3D Abstract will spark new innovative ideas for ... Austin - CEO of Pixel Film Studios. , Create an abstract backdrop animation ... ability to generate and manipulate three-dimensional shapes with ease all within Final Cut Pro ...
(Date:5/31/2016)... ... May 31, 2016 , ... Fire ... CDC, has joined the Fire Door Solutions’ team. Keith will serve Fire ... and frame in-field re-labeling. He will be instrumental in developing educational curriculum ...
(Date:5/31/2016)... ... , ... Splashtop Inc., the worldwide leader in high performance cross-screen access, ... leading provider of secure mobile remote access solution for Japan enterprises. , ... solution. Splashtop for CACHATTO will be available as an integrated add-on secure ...
(Date:5/31/2016)... ... May 31, 2016 , ... DDL, Inc. announced today it has expanded ... (A2LA) to include ISO 594-1 and ISO 594-2 testing for conical (Luer) fittings. ... connection between two medical devices (e.g. a syringe and hypodermic needle) that carry small ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple ... London is home to Ontario’s leading day spa and one of Canada’s few accredited ... with a unique concept to combine spa services with hair and beauty services ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... May 31, 2016 The global ... progressing at a CAGR of 10.6% within a forecast ... at US$0.46 bn in 2013. Owing to favorable factors ... reach US$0.88 bn by the end of this forecast ... the market,s holistic representation in a research report published ...
(Date:5/31/2016)... , May 31, 2016 CollPlant Ltd. (TASE: ... rhCollagen technology for tissue repair products - announces that ... Israel,s Ministry of Economy, for ... project for 2016. The Chief Scientist,s grant amount to NIS ... which totaled NIS 4.7 million.  The development ...
(Date:5/30/2016)... 2016 According to ... Market by Technology (Single-factor (Fingerprint, Face, Iris, ... (Workforce Management), End User (Hospitals, Healthcare Institutions) ... MarketsandMarkets, the market is projected to reach ... 1,182.6 Million by 2016, at a CAGR ...
Breaking Medicine Technology: